ERBB2 and cholangiocarcinoma: Zanidatamab, the biparatotic targeting HER2 antibody, revealed meaningful activity in clinical trials against HER2-positive CCA (IHC3+ or 2+ and ISH+), such a rapid and durable response, safety profile with ORR: 41%, disease control rate (DCR) 68.8% and duration of response (DoR) 12.9 months [118].